Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Randomized, Double-blinded, Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of BI 425809 Once Daily With Adjunctive Computerized Cognitive Training Over 12 Week Treatment Period in Patients With Schizophrenia

Trial Profile

A Phase II Randomized, Double-blinded, Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of BI 425809 Once Daily With Adjunctive Computerized Cognitive Training Over 12 Week Treatment Period in Patients With Schizophrenia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Iclepertin (Primary)
  • Indications Schizophrenia
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Boehringer Ingelheim

Most Recent Events

  • 07 Nov 2022 Status changed from active, no longer recruiting to completed.
  • 18 Oct 2022 Results(n=183) assessing the efficacy of BI 425809 together with at home computerised cognitive training in patients with schizophrenia as part of a global multicentre trial presented at the 35th Annual Congress of the European College of Neuropsychopharmacology
  • 28 Jun 2022 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top